Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Future Oncol ; 19(10): 727-736, 2023 Mar.
Article in English | MEDLINE | ID: mdl-37133230

ABSTRACT

Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.


Subject(s)
Breast Neoplasms , Humans , Female , Letrozole/therapeutic use , Breast Neoplasms/pathology , Retrospective Studies , Aminopyridines/therapeutic use , Treatment Outcome , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Receptor, ErbB-2
SELECTION OF CITATIONS
SEARCH DETAIL